{"filing":{"accession_number":"0001140361-26-027642","cik":"0001658247","ticker":"CRNX","company_name":"Crinetics Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-07-06","report_date":null,"primary_document":"ef20077399_form8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1658247/000114036126027642/ef20077399_form8k.htm"},"events":[{"id":16252,"run_id":14503,"accession_number":"0001140361-26-027642","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"summary":"Crinetics Pharmaceuticals entered into a definitive merger agreement with Vertex Pharmaceuticals on July 6, 2026, under which Vertex will acquire Crinetics for $85.00 per share in cash, representing approximately $10.0 billion in total equity value (or $8.8 billion net of cash). The transaction is expected to close in Q3 2026, subject to regulatory and shareholder approvals, and adds significant commercial and pipeline assets including PALSONIFY and atumelnant with approximately $5 billion peak sales potential to Vertex's portfolio.","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-07-06","form":"8-K","submitted_at":null,"items":[{"id":14297,"accession_number":"0001140361-26-027642","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"This Item 1.01 discloses Crinetics' entry into a definitive merger agreement with Vertex Pharmaceuticals on July 6, 2026, under which Vertex will acquire Crinetics for $85.00 per share in cash, representing approximately $10.0 billion in total equity value (or $8.8 billion net of cash). The filing details the merger structure, consideration, closing conditions, financing arrangements, and board approval. This is a material acquisition transaction that would substantially affect a reasonable investor's assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:00:04.295449+00:00","company_name":"","ticker":null,"filing_date":""},{"id":14298,"accession_number":"0001140361-26-027642","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"The filing discloses Vertex Pharmaceuticals' execution of a definitive merger agreement to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, representing approximately $10.0 billion in total equity value. This is a material acquisition transaction announced on July 6, 2026, with expected closing in Q3 2026, subject to regulatory and shareholder approvals. The transaction adds significant commercial and pipeline assets (PALSONIFY and atumelnant) with ~$5 billion peak sales potential to Vertex's portfolio.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:00:04.295449+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14297,"accession_number":"0001140361-26-027642","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"This Item 1.01 discloses Crinetics' entry into a definitive merger agreement with Vertex Pharmaceuticals on July 6, 2026, under which Vertex will acquire Crinetics for $85.00 per share in cash, representing approximately $10.0 billion in total equity value (or $8.8 billion net of cash). The filing details the merger structure, consideration, closing conditions, financing arrangements, and board approval. This is a material acquisition transaction that would substantially affect a reasonable investor's assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:00:04.295449+00:00","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-07-06"},{"id":14298,"accession_number":"0001140361-26-027642","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"The filing discloses Vertex Pharmaceuticals' execution of a definitive merger agreement to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, representing approximately $10.0 billion in total equity value. This is a material acquisition transaction announced on July 6, 2026, with expected closing in Q3 2026, subject to regulatory and shareholder approvals. The transaction adds significant commercial and pipeline assets (PALSONIFY and atumelnant) with ~$5 billion peak sales potential to Vertex's portfolio.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:00:04.295449+00:00","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-07-06"}]}